---
title: 'Efficacy and safety of extended duration letermovir prophylaxis in recipients
  of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection:
  a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial'
date: '2023-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38142695/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231225170704&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: In a pivotal phase 3 trial of cytomegalovirus prophylaxis
  with letermovir for up to 100 days after allogeneic haematopoietic stem-cell transplantation
  (HSCT), 12% of participants developed clinically significant cytomegalovirus infection
  after letermovir was discontinued. We aimed to evaluate the efficacy and safety
  of extending the duration of letermovir prophylaxis for clinically significant cytomegalovirus
  infection from 100 days to 200 days following ...'
disable_comments: true
---
BACKGROUND: In a pivotal phase 3 trial of cytomegalovirus prophylaxis with letermovir for up to 100 days after allogeneic haematopoietic stem-cell transplantation (HSCT), 12% of participants developed clinically significant cytomegalovirus infection after letermovir was discontinued. We aimed to evaluate the efficacy and safety of extending the duration of letermovir prophylaxis for clinically significant cytomegalovirus infection from 100 days to 200 days following ...